This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Philip, A.
Right arrow Articles by Ostrosky-Zeichner, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Philip, A.
Right arrow Articles by Ostrosky-Zeichner, L.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, August 2005, p. 3572-3574, Vol. 49, No. 8
0066-4804/05/$08.00+0     doi:10.1128/AAC.49.8.3572-3574.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.

In Vitro Synergy Testing of Anidulafungin with Itraconazole, Voriconazole, and Amphotericin B against Aspergillus spp. and Fusarium spp.

Annie Philip, Zekaver Odabasi, Jose Rodriguez, Victor L. Paetznick, Enuo Chen, John H. Rex,{dagger} and Luis Ostrosky-Zeichner*

Laboratory of Mycology Research, Division of Infectious Diseases, University of Texas-Houston Medical School, Houston, Texas 77030

Received 25 January 2005/ Returned for modification 9 March 2005/ Accepted 6 May 2005


arrow
ABSTRACT
 
The in vitro interactions of anidulafungin with itraconazole, voriconazole, and amphotericin B were evaluated by using the checkerboard method. For Aspergillus spp., anidulafungin with amphotericin B showed indifference for 16/26 isolates, while anidulafungin with either azole showed a synergy trend for 18/26 isolates. All drug combinations showed indifference for 7/7 Fusarium sp. isolates.


arrow
TEXT
 
Invasive fungal infections due to molds are becoming more prevalent in immunocompromised patients (21). Among the invasive mold infections, Aspergillus spp. and Fusarium spp. are particularly challenging to manage, due to aggressive courses and high mortality (11, 20).

Since 1959, amphotericin B deoxycholate (AMBD) had been considered the "gold standard" for the treatment of fungal infections. However, due to high failure rates and significant toxicity (6), other agents are being explored today both singly and in combination therapy. Among the azoles, itraconazole (ITR) continues to show some promise against Aspergillus spp. (3). Voriconazole (VOR), a novel azole (11), is perhaps the current "gold standard" for the treatment of invasive aspergillosis, although success rates are still less than optimal (5, 8). The echinocandins (caspofungin, anidulafungin [ANID], and micafungin) inhibit 1,3-ß-D-glucan synthesis and have in vitro and in vivo activity against Candida and Aspergillus spp. (4, 16, 17). In the clinical setting, caspofungin appears to be at least as effective as AMBD for salvage therapy of invasive aspergillosis compared to historical controls (13).

Due to the high mortality and lack of an ideal drug for these diseases, combination therapy has been an attractive possibility that has recently received much attention in medical mycology. Early studies have shown in vitro and in vivo advantages of several combinations. Arikan et al. (2) showed additive to synergistic effects of caspofungin with AMBD in vitro against Aspergillus and Fusarium spp. In a guinea pig model, colony counts of Aspergillus spp. and the number of culture-positive tissues were reduced after treatment with VOR and caspofungin compared with either of the agents alone (10). Similarly, Petraitis et al. showed that the combination of micafungin and ravuconazole in a rabbit model had synergistic effects against invasive aspergillosis (18).

The purpose of this study was to evaluate the in vitro interactions of ITR, VOR, and AMBD with ANID against Aspergillus spp. and Fusarium spp. as preliminary work to support further in vivo and clinical research on these combinations.

Isolates. Twenty-six clinical isolates of Aspergillus spp. and seven clinical isolates of Fusarium spp. were used. The species distribution was as follows: eight isolates of Aspergillus flavus, eight isolates of A. fumigatus, five isolates of A. niger, five isolates of A. terreus, two isolates of Fusarium oxysporum, and five isolates of F. solani.

Drugs and synergy testing. Pure powders of ITR (Janssen), VOR (Pfizer), ANID (Vicuron), and AMBD (Bristol-Myers Squibb) were dissolved to obtain stock concentrations of 6,400 mg/ml. Serial dilutions were made to 6.25 mg/ml. Checkerboard testing was carried out in RPMI 2% glucose in microdilution plates by using elements from the CLSI (formerly NCCLS) M-38A and M-27A2 methods (14, 15). Drug dilutions in twofold increments were prepared at fourfold levels above the desired final concentration for each drug tested. Each of the wells contained combination drug dispensed at 50 µl each, effectively creating a 2x concentration of each drug. Plates were stored at –70°C until inoculation. Conidia of mold isolates were harvested, and the suspension was spectrophotometrically adjusted to 0.5 McFarland turbidity standard. A total of 0.1 ml of each mold suspension was dispensed into serially diluted wells containing the drugs, reaching the final targeted drug concentration. The potency and concentration of the drugs in the final plates were verified by testing the single drug row and column with quality control strains as outlined in the CLSI methods, and the experiment was performed only once.

Plates were incubated at 35°C and read at 24 and 48 h. MICs and fractional inhibitory concentration indices (FICIs) were visually read and determined at the optically clear (MIC-0) and prominent growth reduction (MIC-2) endpoints. The FICI was then calculated and interpreted according to standard procedures (1, 9): FICIs of ≤0.5 signified synergy, and FICIs of >4.0 signified antagonism. Values between 0.5 and 4 were considered indifferent.

Table 1 shows the mean (range) FICI values for the different drug combinations at 48 h, and Table 2 shows categorical interpretations using the MIC-2 endpoint (which correlates well with the minimal fungicidal concentration, the suggested endpoint for echinocandins). Synergy between ANID and both azoles was observed in 18 of 26 isolates of Aspergillus spp. Synergy was most often observed with A. fumigatus and A. flavus. With ANID and AMBD, indifference was most often seen; synergy and antagonism were seen with five strains each of Aspergillus spp. at 48 h and MIC-2 endpoints. For Fusarium spp., all drug combinations suggested indifference. Antagonism between ANID and azoles was rare. This was seen with ANID and ITR against a single Aspergillus strain under the test conditions of Table 2 and was not consistently seen with any strain under all four test conditions (MIC-0 and MIC-2 at 24 and 48 h). Paradoxically, increased growth (7) was observed at the highest concentration of ANID and AMBD for 90% of Fusarium sp. isolates and 28% of Aspergillus sp. isolates.


View this table:
[in this window]
[in a new window]
  		TABLE 1. Mean (range) MIC-0 and MIC-2 FICI values at 48 hours for 26 Aspergillus sp. and 7 Fusarium sp. isolates


View this table:
[in this window]
[in a new window]
  		TABLE 2. Categorical interpretation of FICI results for 26 Aspergillus sp. isolates and 7 Fusarium sp. isolates by using MIC-2 at 48 h

Although with limited numbers and having a moderate effect at most, this in vitro study presents data showing that ANID frequently exhibits in vitro synergy with VOR and ITR when tested against Aspergillus spp. Synergism in vitro has been reported for Aspergillus spp. with triazoles used in combination with caspofungin (E. K. Manavathu, G. J. Alangaden, and P. H. Chandrasekar, Abstr. 42nd Intersci. Conf. Antimicrob. Agents Chemother., abstr. M-854, 2002), and a previous in vitro study suggested potential synergistic to additive effects of caspofungin in combination with AMBD against Fusarium spp. (2). In the present study, activity against Fusarium was limited, as shown by the findings of indifference for all drugs in all seven isolates.

The significance of the paradoxical "Eagle-like" effect we observed with the AMBD combination is unknown. This was observed frequently for Fusarium spp. (against which ANID alone is inactive) and much less frequently for Aspergillus spp. and only at the highest concentrations of the drugs. This effect has been previous described for echinocandins and Candida albicans (19).

Although the checkerboard method has not been standardized for testing molds, it has the advantage of simplicity in performance and interpretation (12). The lack of correlation between this method and Etest, time-kill curves, or in vivo outcomes makes its usefulness for determining definitive synergy open to debate (9). Nevertheless, the potential synergy of azoles and echinocandins has been supported by an in vivo guinea pig model of disseminated aspergillosis with reduced colony counts in liver, lung, kidney, or brain tissues (10). Similarly, results with an experimental rabbit model of invasive pulmonary aspergillosis suggested decreasing serum galactomannan levels, burden of organisms, and overall mortality with such combinations (18). Both in vitro and animal model data suggest that further in vivo evaluation of ANID combinations, particularly with the azoles and against Aspergillus spp., is warranted.


arrow
ACKNOWLEDGMENTS
 
This work was supported by a grant from Vicuron Pharmaceuticals, Inc.


arrow
FOOTNOTES
 
* Corresponding author. Mailing address: Laboratory of Mycology Research, Division of Infectious Diseases, University of Texas—Houston Medical School, 6431 Fannin, MSB 2.112, Houston, TX 77030. Phone: (713) 500-6733. Fax: (713) 500-5495. E-mail: Luis.Ostrosky-Zeichner{at}uth.tmc.edu. Back

{dagger} Present address: AstraZeneca Pharmaceuticals, Alderley House, Alderley Park, Macclesfield, United Kingdom. Back


arrow
REFERENCES
 
    1
  1. American Society for Microbiology. 2004. Instructions to authors. Antimicrob. Agents Chemother. 48:i-xx.
    2. 2
  2. Arikan, S., M. Lozano-Chiu, V. Paetznick, and J. H. Rex. 2002. In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp. Antimicrob. Agents Chemother. 46:245-247.[Abstract/Free Full Text]
    3. 3
  3. Carrillo-Munoz, A. J., M. Ruesga, S. Brio, O. del Valle, V. Rodriguez, P. Santos, J. M. Hernandez-Molina, E. Canton, J. Peman, J. Guarro, and G. Quindos. 2002. Comparison of in vitro antifungal activities of amphotericin B lipid complex with itraconazole against 708 clinical yeast isolates and opportunistic moulds determined by National Committee for Clinical Laboratory Standards methods M27-A and M38-P. Chemotherapy 48:224-231.[Medline]
    4. 4
  4. Cornely, O. A., K. Schmitz, and S. Aisenbrey. 2002. The first echinocandin: caspofungin. Mycoses 45(Suppl. 3):56-60.
    5. 5
  5. Denning, D. W., P. Ribaud, N. Milpied, D. Caillot, R. Herbrecht, E. Thiel, A. Haas, M. Ruhnke, and H. Lode. 2002. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin. Infect. Dis. 34:563-571.[CrossRef][Medline]
    6. 6
  6. Dismukes, W. E. 2000. Introduction to antifungal drugs. Clin. Infect. Dis. 30:653-657.[CrossRef][Medline]
    7. 7
  7. Eagle, H. 1952. Experimental approach to the problem of treatment failure with penicillin. I. Group A streptococcal infection in mice. Am. J. Med. 13:389-399.[CrossRef][Medline]
    8. 8
  8. Herbrecht, R., D. W. Denning, T. F. Patterson, J. E. Bennett, R. E. Greene, J. W. Oestmann, W. V. Kern, K. A. Marr, P. Ribaud, O. Lortholary, R. Sylvester, R. H. Rubin, J. R. Wingard, P. Stark, C. Durand, D. Caillot, E. Thiel, P. H. Chandrasekar, M. R. Hodges, H. T. Schlamm, P. F. Troke, and B. de Pauw. 2002. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N. Engl. J. Med. 347:408-415.[Abstract/Free Full Text]
    9. 9
  9. Johnson, M. D., C. MacDougall, L. Ostrosky-Zeichner, J. R. Perfect, and J. H. Rex. 2004. Combination antifungal therapy. Antimicrob. Agents Chemother. 48:693-715.[Free Full Text]
    10. 10
  10. Kirkpatrick, W. R., S. Perea, B. J. Coco, and T. F. Patterson. 2002. Efficacy of caspofungin alone and in combination with voriconazole in a guinea pig model of invasive aspergillosis. Antimicrob. Agents Chemother. 46:2564-2568.[Abstract/Free Full Text]
    11. 11
  11. Kontoyiannis, D. P., E. Mantadakis, and G. Samonis. 2003. Systemic mycoses in the immunocompromised host: an update in antifungal therapy. J. Hosp. Infect. 53:243-258.[CrossRef][Medline]
    12. 12
  12. Lewis, R. E., D. J. Diekema, S. A. Messer, M. A. Pfaller, and M. E. Klepser. 2002. Comparison of Etest, chequerboard dilution and time-kill studies for the detection of synergy or antagonism between antifungal agents tested against Candida species. J. Antimicrob. Chemother. 49:345-351.[Abstract/Free Full Text]
    13. 13
  13. Maertens, J., I. Raad, G. Petrikkos, M. Boogaerts, D. Selleslag, F. B. Petersen, C. A. Sable, N. A. Kartsonis, A. Ngai, A. Taylor, T. F. Patterson, D. W. Denning, and T. J. Walsh. 2004. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin. Infect. Dis. 39:1563-1571.[CrossRef][Medline]
    14. 14
  14. NCCLS. 2002. M-38A: reference method for broth dilution antifungal susceptilibity testing of filamentous fungi: approved standard. NCCLS, Wayne, Pa.
    15. 15
  15. NCCLS. 2002. M-27A2: reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard, 2nd ed. NCCLS, Wayne, Pa.
    16. 16
  16. Petraitiene, R., V. Petraitis, A. H. Groll, T. Sein, R. L. Schaufele, A. Francesconi, J. Bacher, N. A. Avila, and T. J. Walsh. 2002. Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: pharmacokinetics, drug disposition, and relationship to galactomannan antigenemia. Antimicrob. Agents Chemother. 46:12-23.[Abstract/Free Full Text]
    17. 17
  17. Petraitis, V., R. Petraitiene, A. H. Groll, A. Bell, D. P. Callender, T. Sein, R. L. Schaufele, C. L. McMillian, J. Bacher, and T. J. Walsh. 1998. Antifungal efficacy, safety, and single-dose pharmacokinetics of LY303366, a novel echinocandin B, in experimental pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob. Agents Chemother. 42:2898-2905.[Abstract/Free Full Text]
    18. 18
  18. Petraitis, V., R. Petraitiene, A. A. Sarafandi, A. M. Kelaher, C. A. Lyman, H. E. Casler, T. Sein, A. H. Groll, J. Bacher, N. A. Avila, and T. J. Walsh. 2003. Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin. J. Infect. Dis. 187:1834-1843.[CrossRef][Medline]
    19. 19
  19. Stevens, D. A., M. Espiritu, and R. Parmar. 2004. Paradoxical effect of caspofungin: reduced activity against Candida albicans at high drug concentrations. Antimicrob. Agents Chemother. 48:3407-3411.[Abstract/Free Full Text]
    20. 20
  20. Stevens, D. A., V. L. Kan, M. A. Judson, V. A. Morrison, S. Dummer, D. W. Denning, J. E. Bennett, T. J. Walsh, T. F. Patterson, G. A. Pankey, et al. 2000. Practice guidelines for diseases caused by Aspergillus. Clin. Infect. Dis. 30:696-709.[CrossRef][Medline]
    21. 21
  21. Vartivarian, S. E., E. J. Anaissie, and G. P. Bodey. 1993. Emerging fungal pathogens in immunocompromised patients: classification, diagnosis, and management. Clin. Infect. Dis. 17(Suppl. 2):S487-S491.

Antimicrobial Agents and Chemotherapy, August 2005, p. 3572-3574, Vol. 49, No. 8
0066-4804/05/$08.00+0     doi:10.1128/AAC.49.8.3572-3574.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Crandon, J. L., Banevicius, M. A., Fang, A. F., Crownover, P. H., Knauft, R. F., Pope, J. S., Russomanno, J. H., Shore, E., Nicolau, D. P., Kuti, J. L. (2009). Bronchopulmonary Disposition of Intravenous Voriconazole and Anidulafungin Given in Combination to Healthy Adults. Antimicrob. Agents Chemother. 53: 5102-5107 [Abstract] [Full Text]  
  • Spreghini, E., Orlando, F., Santinelli, A., Pisa, E., Loretelli, C., Manso, E., Milici, M. E., Scalise, G., Barchiesi, F. (2009). Anidulafungin in Combination with Amphotericin B against Aspergillus fumigatus. Antimicrob. Agents Chemother. 53: 4035-4039 [Abstract] [Full Text]  
  • Nagasaki, Y., Eriguchi, Y., Uchida, Y., Miyake, N., Maehara, Y., Kadowaki, M., Harada, M., Akashi, K., Shimono, N. (2009). Combination therapy with micafungin and amphotericin B for invasive pulmonary aspergillosis in an immunocompromised mouse model. J Antimicrob Chemother 64: 379-382 [Abstract] [Full Text]  
  • van de Sande, W. W. J., Mathot, R. A. A., ten Kate, M. T., van Vianen, W., Tavakol, M., Rijnders, B. J. A., Bakker-Woudenberg, I. A. J. M. (2009). Combination Therapy of Advanced Invasive Pulmonary Aspergillosis in Transiently Neutropenic Rats Using Human Pharmacokinetic Equivalent Doses of Voriconazole and Anidulafungin. Antimicrob. Agents Chemother. 53: 2005-2013 [Abstract] [Full Text]  
  • O'Donnell, K., Sutton, D. A., Fothergill, A., McCarthy, D., Rinaldi, M. G., Brandt, M. E., Zhang, N., Geiser, D. M. (2008). Molecular Phylogenetic Diversity, Multilocus Haplotype Nomenclature, and In Vitro Antifungal Resistance within the Fusarium solani Species Complex. J. Clin. Microbiol. 46: 2477-2490 [Abstract] [Full Text]  
  • Perkhofer, S., Jost, D., Dierich, M. P., Lass-Florl, C. (2008). Susceptibility Testing of Anidulafungin and Voriconazole Alone and in Combination against Conidia and Hyphae of Aspergillus spp. under Hypoxic Conditions. Antimicrob. Agents Chemother. 52: 1873-1875 [Abstract] [Full Text]  

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Philip, A.
Right arrow Articles by Ostrosky-Zeichner, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Philip, A.
Right arrow Articles by Ostrosky-Zeichner, L.

Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»